This test is most useful if any of these apply to you.
A stool Clostridium result describes part of your gut bacterial community. Its use for diagnosing illness, confirming recovery after antibiotics, or choosing a treatment remains exploratory. There is no established genus-level target that separates a healthy gut from an unhealthy one.
The species grouped under this name have different effects. Some produce compounds used by your colon lining, while some strains can cause disease. A total for the group doesn't establish which of those activities is occurring.
This result estimates the abundance of Clostridium bacteria from DNA in your stool. It describes organisms represented in the collected sample. It does not directly measure toxin production, fermentation activity, or the condition of your intestinal lining.
Abundance also needs to be distinguished from activity. Detecting bacterial DNA doesn't establish that the organisms are alive or producing a particular substance. A genus-level result combines species and strains that may differ in both respects.
Clostridium is a genus, a group of related bacterial species. Clostridia is a much broader class containing many genera. Older studies also use numbered clostridial clusters, including XI, XIVa, and XIVb. Those historical groups include bacteria outside the modern Clostridium genus, so their findings cannot automatically be applied to this result.
Some Clostridium species can produce butyrate. Butyrate is a fermentation product that colon-lining cells use as fuel. Other species include strains capable of producing disease-causing toxins. Even finding a species such as Clostridium perfringens does not establish illness, because toxin-producing capacity and the circumstances of infection matter.
Clostridioides difficile was formerly called Clostridium difficile but now belongs to a separate genus. Research on that organism concerns a specific infection and specific diagnostic tests. A general Clostridium abundance result cannot establish whether it is present.
Antibiotics can disrupt bacteria that help resist C. difficile colonization and infection. The resulting changes involve many organisms, and different species can increase or decrease. The total Clostridium result cannot show whether that protection has been lost or restored.
In a study of hospitalized adults receiving broad-spectrum antibiotics, carrying toxin-capable C. difficile was associated with a markedly higher risk of later infection. This finding came from targeted rectal-swab testing for C. difficile, a different organism and measurement from stool Clostridium abundance. There were too few infections to adjust the estimate for other risk factors, so the study did not establish that carriage predicted infection independently of those factors.
C. difficile can be carried without causing symptoms. Its molecular tests detect genes, including genes that allow toxin production. Tests for free toxin look for the toxin protein in stool. These results answer different questions, and neither should be interpreted without the clinical picture.
In a study of 1,416 hospitalized adults, people who were positive by molecular testing but negative by the stool toxin assay generally had outcomes similar to those who tested negative by both methods. That finding supports concern about overdiagnosis when molecular results are used without suitable symptoms. But toxin assays can miss some infections, so a negative toxin result does not rule out disease in every symptomatic person.
A study comparing ulcerative colitis with and without C. difficile infection found differences across several clostridial groups. Clostridium sensu stricto and historical cluster XI were more abundant in the group with both conditions, while cluster XIVb was depleted. These were stool associations across different bacterial groups. They did not establish that a higher total Clostridium result causes inflammation or measures its severity.
Research in irritable bowel syndrome has also found relationships between particular bacteria, stool fermentation products, and bowel patterns. These findings do not establish a genus-level Clostridium signature that can diagnose IBS, distinguish its causes, or explain an individual episode of diarrhea.
A study with test and validation cohorts totaling 1,037 people examined a separate, species-specific stool measurement of Clostridium symbiosum. Its abundance increased across groups with advanced adenomas and colorectal cancer, and it distinguished early cancer from controls better than the fecal immunochemical test in those selected cohorts.
That finding concerns a targeted species assay. It does not establish cancer risk from a total Clostridium result or validate this genus measurement as a replacement for established colorectal cancer screening.
Stool bacterial abundance can change substantially over time. In a six-week study using daily sampling, variation within the same person exceeded differences between people for 78% of the genera studied. That finding concerned absolute abundance measured with cell counting and sequencing. It was not a Clostridium-specific estimate, and it does not mean every single sample is uninformative.
Gut communities have both stable and changing features. In a study of adult men sampled over about six months, bacterial composition remained more similar within a person than between different people. Repeated measurements can document change, but a rising or falling Clostridium total has not been validated as evidence that your gut health improved or worsened.
Clostridium is best interpreted alongside these tests.
Clostridium is included in these pre-built panels.
See what your gut microbes are actually doing, not just whether your digestion feels off, and track the balance over time.